Hot Stock Alert:

(NASDAQ: CVKD)

Add This Stock to Your Watchlist Immediately — Here’s Why

Cadrenal (CVKD) has FDA backing, Abbott ties, and a Phase 3-ready drug targeting high-risk heart patients. Almost no one’s watching — but you should.

Full breakdown below.

logologologologologo
sms
smsEnter your phone number
investors

Join 128,000 smart investors. Subscribe today.

arrow

*Sponsored

CVKD: Phase 3-Ready Biotech with FDA Backing and a Quiet Partnership That Could Matter

  • Ticker: CVKD
  • Exchange: NASDAQ
  • Float: Tight
  • Sector: Cardiovascular Biopharma
  • Stage: Phase 3-Ready
  • Status: Still off most people’s radar

Let’s get straight to the signal.

Cadrenal Therapeutics (CVKD) is a clinical-stage biotech preparing to launch a pivotal trial for a drug that targets patients who literally don’t have safer options. Their lead candidate, Tecarfarin, isn’t a maybe. It’s a ready-to-run Phase 3 asset that’s already passed through 11 trials and has FDA fast track and orphan drug designations.

And almost nobody is watching.

What’s the play here?

Cadrenal (CVKD) is developing Tecarfarin, an oral blood thinner designed for patients with implanted heart pumps (LVADs), advanced kidney disease, or both. These are high-risk patients—millions of them globally—who still rely on warfarin, a 70-year-old drug known for unpredictable effects and a laundry list of complications.

Tecarfarin is designed to do the same job as warfarin—but in a safer, smarter way. Instead of going through the liver’s busy processing system (like warfarin does), it takes a cleaner path through the body. That could mean fewer side effects, fewer problems with other medications or food, and more consistent results for patients.

This isn’t early science. This is late-stage biotech with data.

Let’s talk facts

  • 11 clinical trials completed
  • 1,000+ patients studied
  • In the pivotal Phase 2/3 trial, Tecarfarin showed:
  • Fewer major bleeds than warfarin
  • Zero thrombotic events in the Tecarfarin group
  • Cadrenal (CVKD) has manufacturing underway at a U.S.-based CDMO
  • Tecarfarin has Orphan Drug Designation for LVAD patients
  • Also has Fast Track + Orphan Drug for kidney disease + AFib patients

This is a Phase 3-ready asset in a space dominated by old drugs and unmet needs.

Then there's Abbott.

Cadrenal (CVKD) announced it’s working with Abbott on its upcoming Phase 3 trial. Abbott manufactures the HeartMate 3™, the only FDA-approved LVAD device on the U.S. market.

This isn’t a licensing deal (yet), but if Tecarfarin becomes the go-to blood thinner for HeartMate 3 patients, the downstream implications could be serious.

Cadrenal (CVKD) now has product in motion, trial prep in progress, and a collaborative effort with a $200B healthcare powerhouse.

The market is massive and overlooked

  • LVAD patients: Lifelong anticoagulation required
  • Warfarin: Still the standard, still risky
  • Many newer blood thinners: Often contraindicated
  • Cost of complications: Intracranial bleeds average $54,100 per event

Tecarfarin is positioned to replace warfarin in the hardest-to-treat patients. It’s not competing for healthy hearts—it’s solving for the sickest, most complex cases.

What comes next?

  • Phase 3 trial launch: coming
  • Manufacturing ramp: in progress
  • Institutional attention: not here yet

The setup is what we look for:

  • Clear catalyst
  • Real data
  • Strategic positioning
  • FDA support
  • Low awareness

The valuation? It still reflects early-stage attention, not late-stage potential.

Bottom line

Cadrenal (CVKD) is building something real in a space with few innovators and a long runway. The science is tight, the risk is well-defined, and the upside is tied to events—not emotion. It doesn’t need hype.

It just needs time.

Watch this name.

Sponsored Content Disclosure:

This is a paid advertisement. We have been compensated for creating and distributing this content. It is not investment advice or a recommendation to buy or sell any security. Investing involves risk, including the loss of your entire investment. Do your own research and consult a licensed financial advisor.

Full disclaimer below.

Enjoyed This Article?

If you found this breakdown helpful, consider joining Stockverse — a platform designed for investors who value early access to thoughtful stock research and market insights. Your membership includes:

  • Alerts on emerging companies
  • Real-time news, technical data, and market updates
  • Access to StockverseGPT, a research tool for exploring stock-related questions
  • Tools to manage your watchlist and track your portfolio
  • Independent research across a range of sectors

If you appreciate staying informed and organized in your investing, Stockverse is built for you. Sign up atStockverse.com/register
Informed decisions start with the right tools.

STOCK INFORMATION

neov

Cadrenal Therapeutics, Inc.

CVKD neov Nasdaq Stock Market

February 26

Upcoming Earnings

EPS

Market cap

USD (%)

Market Closed (as of 06:29 GMT+5:30)

Add CVKD to your watchlist today

3333

― Join StockVerse Alerts Today!

Winning Stock Picks Sent To Inbox

Sign up for our newsletter to receive the latest updates, insights, and exclusive Winning Stock Picks. As of 2024, our alerts are up a total of 873.22%.

— Your Next Winning Stock Awaits!

Grow Your Wealth by +673.66%! Sign Up Now for Exclusive Stock Picks and Alerts

Phone

By submitting this form and signing up for texts, you consent to receive marketing text messages (e.g., promos, cart reminders) from Relqo Media at the number provided, including messages sent by autodialer. Consent is not a condition of purchase. Msg & data rates may apply. Msg frequency varies. Unsubscribe at any time by replying STOP or clicking the unsubscribe link (where available). Privacy Policy & Terms.

american-flagUSA

1309 coffeen ave suite 1200

sheridan wyoming 84403
www.stockverse.com

— Follow Us

imgStockverse Logo
close

Winning Stock Picks

Grow Your Wealth by +673.66%! Get Exclusive Stock Picks Sent To Your Inbox!

Phone

By submitting this form and signing up for texts, you consent to receive marketing text messages (e.g., promos, cart reminders) from Relqo Media at the number provided, including messages sent by autodialer. Consent is not a condition of purchase. Msg & data rates may apply. Msg frequency varies. Unsubscribe at any time by replying STOP or clicking the unsubscribe link (where available). Privacy Policy & Terms.

MASTER LEGAL DISCLAIMER

Effective Date: August 2024

Last Updated: May 17, 2025

Publisher: Relqo Media LLC (Wyoming, United States)

Subject Company: Cadrenal Therapeutics, Inc. (CVKD)

IMPORTANT SUMMARY — PLEASE READ FIRST

This website and any affiliated digital materials are published by Relqo Media LLC, a Wyoming marketing agency that has been compensated in cash by Genesis One Holdings LLC to produce and distribute promotional content regarding Cadrenal Therapeutics, Inc. (NASDAQ: CVKD). This communication is a paid advertisement, not a research report, not investment advice, and not an independent publication. Relqo Media is not a broker-dealer, investment adviser, or securities analyst. Investing in small-cap or microcap securities is extremely speculative and may result in the total loss of your investment. We strongly urge all viewers to consult a licensed investment professional and perform their own due diligence.

1. NATURE AND INTENT OF THIS COMMUNICATION

Relqo Media LLC is a for-profit marketing agency engaged in paid promotions of public companies. The content we produce is strictly commercial and intended to create temporary public awareness, visibility, and short-term market activity around the featured company. This material is not impartial. All readers should interpret our content as a paid commercial advertisement and not as an editorial, research article, or independent commentary. We create advertisements, not analysis. These Communications are not intended to be factual evaluations of the company’s operations or investment merit.

2. COMPENSATION FOR CADRENAL THERAPEUTICS, INC. (CVKD)

Relqo Media LLC has been retained by Genesis One Holdings LLC to provide promotional media services for Cadrenal Therapeutics, Inc. (NASDAQ: CVKD). As of the effective date:

  • Relqo Media LLC is receiving cash compensation for digital investor awareness campaigns.
  • The total compensation paid for these services is $25,000 per week, paid weekly, for the period beginning January 1, 2025, through July 1, 2025, totaling $650,000.
  • A new agreement has been entered into for a continuation of services at the same rate of $25,000 per week, paid weekly, for a 30-day period from June 26, 2025, through July 26, 2025, totaling an additional $100,000 in compensation.
  • Genesis One Holdings LLC may own, acquire, or dispose of shares in CVKD during or after the campaign period.

This relationship creates a material conflict of interest. Relqo Media’s content regarding CVKD should be considered promotional, biased, and financially motivated.

3. INTENDED AUDIENCE

These Communications are directed solely to U.S.-based, self-directed investors who understand the risks of investing in microcap and Nasdaq-listed securities. The content is not intended for children, seniors, retirement accounts, or individuals with limited experience in securities trading. These Communications are not intended to guide investment for long-term portfolio management or financial planning purposes.

4. NO ENDORSEMENT OR VERIFICATION OF COMPANY CLAIMS

Relqo Media LLC does not independently verify, investigate, or audit any statements made by the company being promoted, its officers, its press releases, or any third-party sources. Any claims, projections, customer announcements, or product statements made in connection with CVKD should be assumed to be unverified and potentially inaccurate unless independently confirmed. You should not rely on any statements regarding future performance, partnerships, revenue projections, or corporate plans.

5. MARKET INFLUENCE AND TRADING PATTERN EXPECTATION

Promotional campaigns commonly result in short-lived spikes in stock price and volume, followed by rapid declines. These spikes are typically driven by retail speculation, promotional circulation, and momentary investor interest—not fundamentals. You should expect that:

  • CVKD’s stock may increase temporarily during this promotion,
  • Trading volume may rise sharply, and
  • The price may fall after the campaign ends or selling begins.

These patterns are typical of stock promotions, and you should proceed accordingly.

6. NO RELIANCE – INVESTOR RESPONSIBILITY

The burden of research, investigation, and risk assessment rests solely with you. Relqo Media LLC is not responsible for your investment decisions. You are strongly urged to:

  • Read public filings from the SEC,
  • Consult a licensed financial adviser,
  • Understand risks such as dilution, insider selling, and volatility, and
  • Recognize that speculative stocks often lack financial transparency.

We accept no responsibility for losses incurred due to actions taken based on our Communications.

7. FORWARD-LOOKING STATEMENTS AND SAFE HARBOR

Our materials may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements about potential growth, revenue forecasts, market opportunity, strategic partnerships, or technological development. Such statements are speculative and based on assumptions that may never occur. Actual results may differ materially. These statements are made under the safe harbor protections of Sections 27A and 21E of the Securities Acts. Relqo Media disclaims any duty to update them.

8. INFORMATION SOURCING, BIAS, AND ACCURACY

We use publicly available information including company websites, press releases, and promotional materials supplied by paying clients or related parties. We do not verify or validate this data.

Assume all information presented by Relqo Media is:

  • Subjective,
  • Not independently verified,
  • Created to highlight potential upside and omit downsides,
  • Not suitable as the basis for any investment decision.

9. OWNERSHIP AND TRADING CONFLICTS

Relqo Media LLC, its contractors, members, and affiliates may hold or acquire shares in the companies we promote, including CVKD. We may buy or sell such shares without prior notice. These transactions may occur before, during, or after a promotional campaign and may affect market pricing. We are not obligated to update readers on our trading activity or affiliate holdings.

10. MARKETING TOOLS, DATA COLLECTION, AND USER CONSENT

We use a range of outreach and promotional tools, including:

  • Email and newsletter distributions,
  • SMS/MMS text campaigns,
  • Social media posts and influencers,
  • Google and native display ads,
  • Press releases, video marketing, and paid content distribution.

By engaging with our content, you consent to receive ongoing marketing communications. You may unsubscribe, but your data may be retained for audit or compliance purposes. Please refer to our Privacy Policy for further details.

11. ADVERTISING LAW COMPLIANCE

Relqo Media LLC produces promotional content in accordance with the advertising disclosure standards set forth by the Federal Trade Commission (FTC) and the SEC’s interpretations of sponsored investment-related communications.

We make good-faith efforts to disclose all:

  • Compensation arrangements,
  • Conflicts of interest,
  • Risks,
  • Limitations of our role, and
  • The promotional nature of this content.

We do not provide investment recommendations under any regulatory framework including, but not limited to, SEC Regulation Analyst Certification, FINRA Rule 2210, or Regulation Best Interest.

12. NON-U.S. USERS

This material is intended solely for distribution within the United States. If you are accessing this site from outside the U.S., you are responsible for complying with your country’s laws. Relqo Media disclaims liability for access from non-U.S. jurisdictions where investor promotion, marketing, or solicitation of securities is restricted or prohibited.

13. DISCLAIMER OF WARRANTIES AND LIMITATION OF LIABILITY

All content is provided “as-is” and without warranties of any kind, either express or implied. Relqo Media LLC disclaims any and all liability for:

  • Investment losses,
  • Inaccuracies,
  • Technical delays,
  • User misunderstandings,
  • Omissions or errors in content.

Total liability for any claim shall not exceed one hundred dollars ($100).

14. LEGAL GOVERNANCE AND DISPUTE RESOLUTION

All matters arising out of this disclaimer shall be governed by the laws of the State of Wyoming. You agree that any dispute shall be resolved exclusively through binding arbitration under the rules of the American Arbitration Association, to be held in Sheridan County, Wyoming. Class action claims and group arbitration are expressly prohibited.

15. NON-SOLICITATION AND GEOGRAPHIC LIMITATIONS

Nothing in our content constitutes a general solicitation or a personal securities recommendation. If you reside in a jurisdiction where such communications are unlawful, you must exit this site and discontinue engagement with our content.

16. FINAL NOTICE – ACCEPTANCE OF TERMS

We reserve the right to update this Disclaimer at any time without notice. Your continued use of our services or content constitutes acceptance of the most recent version.

If you do not accept all terms of this disclaimer in full, you must:

  • Exit our websites,
  • Unsubscribe from our communications,
  • Discontinue viewing all Relqo Media promotional content.

17. NO RELIANCE

By viewing or engaging with this content, you agree that:

  • You will not rely on any statements made by Relqo Media for investment purposes,
  • You waive any claim that our content was a material factor in your investment decision,
  • You have read, understood, and accepted this disclaimer in full.

© 2024 Relqo Media LLC. All Rights Reserved.

Legal Contact: 📧 support@stockverse.com

Mailing Address: 1309 Coffeen Ave Ste 1200, Sheridan, WY 82801

Affiliate Disclosure: Relqo Media LLC owns and operates Stockverse.com and all affiliated digital properties.